Products are being developed for cognitive disorders with high unmet medical need and with huge market potential globally
Suven Life Sciences Ltd (Suven) has announced the grant of one product patent from Australia, one product patent from Eurasia and one product patent from Europe corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2034.
The granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
Comments are closed.